EMARKETER delivers leading-edge research to clients in a variety of forms, including full-length reports and data visualizations to equip you with actionable takeaways for better business decisions.
In-depth analysis, benchmarks and shorter spotlights on digital trends.
Learn More
Interactive projections with 10k+ metrics on market trends, & consumer behavior.
Learn More
Proprietary data and over 3,000 third-party sources about the most important topics.
Learn More
Industry KPIs
Industry benchmarks for the most important KPIs in digital marketing, advertising, retail and ecommerce.
Learn More
Client-only email newsletters with analysis and takeaways from the daily news.
Learn More
Analyst Access Program
Exclusive time with the thought leaders who craft our research.
Learn More


Our goal at EMARKETER is to unlock digital opportunities for our clients with the world’s most trusted forecasts, analysis, and benchmarks. Spanning five core coverage areas and dozens of industries, our research on digital transformation is exhaustive.
Our Story
Learn more about our mission and how EMARKETER came to be.
Learn More
Rigorous proprietary data vetting strips biases and produces superior insights.
Learn More
Our People
Take a look into our corporate culture and view our open roles.
Join the Team
Contact Us
Speak to a member of our team to learn more about EMARKETER.
Contact Us
See our latest press releases, news articles or download our press kit.
Learn More
Advertising & Sponsorship Opportunities
Reach an engaged audience of decision-makers.
Learn More
Browse our upcoming and past events, recent podcasts, and other featured resources.
Learn More
Tune in to eMarketer's daily, weekly, and monthly podcasts.
Learn More

Pfizer, Alex Therapeutics commercialize a digital therapy to help with smoking

The news: Pfizer is partnering with Swedish digital therapeutics (DTx) company Alex Therapeutics to commercialize a smartphone-based nicotine cessation program (dubbed Eila). Currently, Pfizer is helping get the DTx clinically validated. The companies plan to commercialize the DTx in Germany first, and eventually to other international markets.

The opportunity: Pharma companies are testing the waters in European markets like Germany prior to expanding to the US, since digital therapies are covered by insurance there (and more likely to be used).

  • The pandemic spurred Germany to enact nationwide digital health reforms: For example, it rolled out its Digital Healthcare Act, which entitled all insured individuals to get access to reimbursement for digital health resources, including DTx.
  • Like the US, Germany has a multi-payer healthcare system—so, the widespread rollout of digital health applications and coverage makes for an interesting case study for the US.

Plus: There’s a huge market for nicotine addiction treatment in both Europe and the US.

  • Around 18% of people in the EU are daily smokers.
  • Nicotine addiction is the most common form of addiction in the US, affecting nearly 10% of the US population, per SAMHSA’s 2020 National Survey on Drug Use and Health.
  • And the rapid rise of vaping, particularly among US teens, has caused a surge in nicotine addiction.

The bigger picture: The European market can serve as a stepping stone for FDA approval in the US market.

  • Obtaining a CE mark is much easier than getting FDA approval: Its review process is 3 times shorter and doesn’t require as much clinical evidence as the FDA does.
  • For example, Babylon Health expanded its AI-powered telehealth triaging chatbot service to the US in early 2020 after already running it in Europe.